Drug Pipeline News

Myovant Sciences and Pfizer announces the US Food and Drug Administration has approved Myfembree (relugolix combination tablets) for the once-daily treatment of moderate-to-severe endometriosis-associated pain.

If approved, ibrexafungerp would be the first and only approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the prevention of recurrent vulvovaginal candidiasis (RVVC).

ObsEva plans to drop linzagolix, its leading candidate for the treatment of uterine fibroids, following concerns raised by the FDA.

Mycovia Pharmaceuticals recently announced US availability of oteseconazole capsules for the treatment of recurrent vulvovaginal candidiasis in women without reproductive potential.

The CANDLE open-label sub-study enrolled 24 patients with RVVC who failed to respond to fluconazole treatment, which was given as an initial 3-dose treatment over 7 days.

The US Food & Drug Administration (FDA) sent a response letter to Spero Therapeutics regarding its New Drug Application (NDA) for tebipenem pivoxil hydrobromide (tebipenem HBr) to treat complicated UTIs, saying the application lacks sufficient data.

Results suggest the potential of this oral therapy to address the unmet clinical need for long-term medical treatment for endometriosis.

Evofem Biosciences, Inc. recently announced results of a post hoc analysis of the registrational Phase 3 AMPOWER trial, which investigated the ability of a contraceptive gel consisting of lactic acid, citric acid, and potassium bitartrate (Phexxi; Evofem) to prevent pregnancy.

Currently approved for the treatment of vulvovaginal candidiasis (VVC), and if the sNDA is approved, ibrexafungerp (Brexafemme; Scynexis) would be the first and only oral non-azole medication for the prevention of recurrent VVC.

The US Food and Drug Administration has accepted to review the supplemental New Drug Application for Myfembree for the potential treatment of heavy menstrual bleeding associated with uterine fibroids for up to 2 years.

The US Food and Drug Administration has approved oteseconazole (Vivjoa; Mycovia Pharmaceuticals) to reduce the incidence of recurrent vulvovaginal candidiasis.

These data build upon previous topline results announced in January 2022.

Astellas announced positive data from its study investigating the long-term safety of fezolinetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

Trastuzumab deruxtecan resulted in a statistically significant improvement in progression-free survival and overall survival compared with physician’s choice of chemotherapy in patients with HER2-low unresectable and/or metastatic breast cancer, irrespective of hormone receptor status, meeting the primary and secondary end points of the phase 3 DESTINY-Breast 04 trial.

Patients with acute vulvovaginal candidiasis (VVC) greatly benefited from oral ibrexafungerp (Brexafemme, Scynexis), according to results of a global phase 3 randomized, double-blind, placebo-controlled superiority study published in the international journal of obstetrics and gynecology, BJOG.

Scynexis released data from its pivotal Phase 3 CANDLE study of oral ibrexafungerp (BREXAFEMME) for the prevention of recurrent vulvovaginal candidiasis.

In this exclusive video interview, Michal Elovitz, MD, chief medical advisor at Mirvie, discusses the latest data from the RNA testing platform in predicting preterm birth at the SMFM 42nd Annual Pregnancy Meeting.

Medication can now be used as few as 6 times a year for virologically suppressed adults living with the disease without prior treatments not working or resistance to cabotegravir or rilpivirine.

Sarah Lee, MD, MBA, discusses the use of checkpoint inhibitors in endometrial cancer, research regarding the association between MSI-H, dMMR, and TMB-H disease, and the importance of broad molecular testing to ensure all eligible patients are appropriately matched to immunotherapeutic options.

The drug is used to treat bacterial vaginosis and is a generic version of Bausch Health US LLC’s MetroGel-Vaginal.

A phase 2, multicenter study has found relugolix (Myfembree; Myovant Sciences) significantly decreases menstrual blood loss in women with uterine leiomyomas and is mostly well tolerated. Relugolix is a small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.

Maneesh Jain, CEO and co-founder of Mirvie, a proprietary RNA platform that uses blood samples to predict pregnancy complications such as preeclampsia, sits down with Contemporary OB/GYN to discuss the potential of the test.

Agile Therapeutics, Inc. announced today the U.S. commercial launch of Twirla (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch.